Format

Send to

Choose Destination
Oncotarget. 2018 Oct 23;9(83):35448-35457. doi: 10.18632/oncotarget.26234. eCollection 2018 Oct 23.

Naturally occurring compounds as pancreatic cancer therapeutics.

Author information

1
Department of Psychiatry and Behavioral Sciences, Center for Therapeutic Innovation University of Miami Miller School of Medicine, University of Miami, Miami, FL, USA.
2
Molecular Therapeutics Shared Resource, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.

Abstract

Naturally occurring small molecule compounds have long been in the spotlight of pancreatic cancer research as potential therapeutics to prevent cancer progression and sensitize chemoresistant tumors. The hope is that terminal pancreatic cancer patients receiving aggressive chemotherapy can benefit from an increase in treatment efficacy without adding further toxicity by way of utilizing natural compounds. While preclinical studies on a number of natural compounds, such as resveratrol, curcumin, rapalogs and cannabinoids, show promising preclinical results, little has translated into clinical practice, though a number of other compounds hold clinical potential. Nevertheless, recent advances in compound formulation may increase the clinical utility of these compounds.

KEYWORDS:

curcumin; natural compounds; pancreatic cancer; resveratrol; taxane

Conflict of interest statement

CONFLICTS OF INTEREST SPB is a founder and shareholder of Jupiter Orphan Therapeutics, a University of Miami spinout company developing resveratrol for mucopolysaccharidosis I and Friedreichs Ataxia, but not for cancer. Otherwise the authors have no conflicts of interest to report.

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center